12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Acceleron, Celgene preclinical data

In a mouse model of beta-thalassemia intermedia, ACE-536 significantly increased red blood cell and hemoglobin levels and reduced erythropoietin levels and the size of enlarged spleens vs. controls. Furthermore,...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >